Dietmar Berger returns to big pharma
Sanofi has a new head of development, which the company confirmed on Wednesday with a short tweet: "Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients."
Dietmar Berger has almost 20 years of experience in the field of oncology, and only a scant year ago left big pharma to work for allogeneic T-cell immunotherapy company Atara Biotherapeutics as Global Head of Research and Development. Atara earlier this week confirmed that Novartis Oncology’s Global Head Cell & Gene, Pascale Touchon, was joining the company as CEO, and also confirmed that Dr. Berger had resigned from the company effective as of May 31, 2019.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium